Oak Investment Partners

Exclusive: Big changes at Oak Investment Partners

March 18, 2014: 1:48 PM ET

After raising 13 "generalist" venture capital funds, Oak Investment Partners embarks on a new strategy.

140317154858-oak-investment-partners-620xa

FORTUNE -- Venture capital firm Oak Investment Partners is making a major change to its organizational structure, Fortune has learned.

The bi-coastal firm has traditionally raised "generalist" funds, which have invested over $9 billion in more than 500 companies since 1978. But Oak had some fundraising troubles last time around, raising south of $800 million for a 13th fund that originally was targeting $1.5 billion (which already was a significant decrease from the $2.5 billion it had raised for Fund XI in 2006). Now the firm is abandoning its traditional strategy, instead choosing to raise a pair of Oak-branded funds that will focus on particular sectors.

One of the funds already is in market, and will focus on healthcare and financial technology companies. It is targeting around $400 million, and will be led by Oak partners like Anne Lamot and Andrew Adams. My guess is that its marketing pitch will center around a number of its wins in the healthcare SaaS market, like AthenaHealth (ATHN), BenefitFocus (BNFT) and Castlight (CSLT).

The other will focus on information technology companies, and is expected to begin fundraising later this year or in early 2015.

A source familiar with the situation says that a big driver for the change was that Oak's healthcare and financial technology deals tended to be later-stage, whereas its IT deals tended to be earlier-stage.

According to the Oregon Public Employees Retirement Fund, Oak's 12th fund had a 3.6% internal rate of return (IRR) and 1.16x total value multiple through Q3 2013. Its 13th fund had a 12.5% IRR and 1.2x total value multiple, and was more than 55% called down.

Expect the entire firm to continue investing Fund XIII, and to manage the legacy portfolio.

Sign up for Dan Primack's daily email newsletter on deals and deal-makers: GetTermSheet.com

  • PharMEDium sale a big deal for Oak

    Source: Pharmacy compounding company valued at $900 million.

    FORTUNE -- Private equity firm Clayton Dubilier & Rice today said that it has completed its previously-announced acquisition of a majority stake in PharMEDium from Oak Investment Partners and Baird Capital.

    No financial terms were disclosed, but Fortune has learned that the deal was done at around a $900 million enterprise valuation.

    For Oak this represents around a 6x return on its 2007 investment, when MORE

    - Jan 29, 2014 1:41 PM ET
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.